Fmr LLC Boosts Holdings in LivaNova PLC (NASDAQ:LIVN)

Fmr LLC raised its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 68.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,466 shares of the company’s stock after acquiring an additional 12,735 shares during the quarter. Fmr LLC’s holdings in LivaNova were worth $1,653,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in LIVN. Fifth Third Bancorp increased its holdings in LivaNova by 97.1% during the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after acquiring an additional 332 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in LivaNova by 4.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 506,105 shares of the company’s stock valued at $27,745,000 after acquiring an additional 20,275 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in LivaNova by 18.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,929 shares of the company’s stock valued at $709,000 after acquiring an additional 2,014 shares in the last quarter. Panagora Asset Management Inc. increased its holdings in LivaNova by 29.4% during the 2nd quarter. Panagora Asset Management Inc. now owns 236,176 shares of the company’s stock valued at $12,947,000 after acquiring an additional 53,718 shares in the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of LivaNova by 0.4% during the second quarter. Rhumbline Advisers now owns 183,132 shares of the company’s stock worth $10,039,000 after buying an additional 659 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

LivaNova Trading Down 1.2 %

Shares of NASDAQ LIVN opened at $51.50 on Monday. The stock’s 50 day moving average price is $51.97 and its two-hundred day moving average price is $51.43. LivaNova PLC has a 52-week low of $43.15 and a 52-week high of $64.47. The stock has a market capitalization of $2.80 billion, a P/E ratio of 122.62 and a beta of 0.98. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Wall Street Analyst Weigh In

Several research analysts have weighed in on LIVN shares. StockNews.com downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Monday, November 25th. Mizuho lowered their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Finally, Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $69.17.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.27% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.